BACKGROUND: The Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group (DCOG LATER) developed a guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors (CCS). In this paper, we present the methods, available evidence and final recommendations of our guideline. MATERIALS AND METHODS: A multidisciplinary working group specified clinical questions that should be answered to get to recommendations for the guideline. We carried out short or extensive evidence summaries and determined methodological quality of studies and levels of evidence in order to answer all clinical questions. When evidence was lacking for CCS, we carefully extrapolated evidence from other populations. Final recommendations were based on evidence and consensus. RESULTS: There was high-level evidence for the increased risk of cardiac dysfunction in CCS and its main risk factors. Evidence was lacking regarding the prognosis, diagnosis and treatment of cardiac dysfunction in CCS. We recommended echocardiographic screening for asymptomatic cardiac dysfunction in CCS treated with cardiotoxic treatments and counseling about potential advantages and disadvantages of our screening recommendations. CONCLUSION: The DCOG LATER guideline recommends risk-based screening for asymptomatic cardiac dysfunction in CCS, but it should be noted that recommendations are not completely supported by evidence in CCS.
BACKGROUND: The Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group (DCOG LATER) developed a guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors (CCS). In this paper, we present the methods, available evidence and final recommendations of our guideline. MATERIALS AND METHODS: A multidisciplinary working group specified clinical questions that should be answered to get to recommendations for the guideline. We carried out short or extensive evidence summaries and determined methodological quality of studies and levels of evidence in order to answer all clinical questions. When evidence was lacking for CCS, we carefully extrapolated evidence from other populations. Final recommendations were based on evidence and consensus. RESULTS: There was high-level evidence for the increased risk of cardiac dysfunction in CCS and its main risk factors. Evidence was lacking regarding the prognosis, diagnosis and treatment of cardiac dysfunction in CCS. We recommended echocardiographic screening for asymptomatic cardiac dysfunction in CCS treated with cardiotoxic treatments and counseling about potential advantages and disadvantages of our screening recommendations. CONCLUSION: The DCOG LATER guideline recommends risk-based screening for asymptomatic cardiac dysfunction in CCS, but it should be noted that recommendations are not completely supported by evidence in CCS.
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer Journal: Lancet Oncol Date: 2015-03 Impact factor: 41.316
Authors: Daniel A Mulrooney; Sara E Nunnery; Gregory T Armstrong; Kirsten K Ness; Deokumar Srivastava; F Daniel Donovan; Beth A Kurt; Monika L Metzger; Matthew J Krasin; Vijaya Joshi; Jean-Bernard Durand; Leslie L Robison; Melissa M Hudson; Scott D Flamm Journal: Cancer Date: 2014-07-16 Impact factor: 6.860
Authors: Elizabeth A M Feijen; Wendy M Leisenring; Kayla L Stratton; Kirsten K Ness; Helena J H van der Pal; Huib N Caron; Gregory T Armstrong; Daniel M Green; Melissa M Hudson; Kevin C Oeffinger; Leslie L Robison; Marilyn Stovall; Leontien C M Kremer; Eric J Chow Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Hannah-Rose Mitchell; Xiaomin Lu; Regina M Myers; Lillian Sung; Lyn M Balsamo; William L Carroll; Elizabeth Raetz; Mignon L Loh; Leonard A Mattano; Naomi J Winick; Meenakshi Devidas; Stephen P Hunger; Kelly Maloney; Nina S Kadan-Lottick Journal: Int J Cancer Date: 2015-09-03 Impact factor: 7.396
Authors: Saro H Armenian; Sarah K Gelehrter; Tabitha Vase; Rajkumar Venkatramani; Wendy Landier; Karla D Wilson; Claudia Herrera; Leah Reichman; John-David Menteer; Leo Mascarenhas; David R Freyer; Kalyanasundaram Venkataraman; Smita Bhatia Journal: Clin Cancer Res Date: 2014-06-19 Impact factor: 12.531
Authors: Eric J Chow; Yan Chen; Leontien C Kremer; Norman E Breslow; Melissa M Hudson; Gregory T Armstrong; William L Border; Elizabeth A M Feijen; Daniel M Green; Lillian R Meacham; Kathleen A Meeske; Daniel A Mulrooney; Kirsten K Ness; Kevin C Oeffinger; Charles A Sklar; Marilyn Stovall; Helena J van der Pal; Rita E Weathers; Leslie L Robison; Yutaka Yasui Journal: J Clin Oncol Date: 2014-10-06 Impact factor: 44.544